SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 3, 2004
IntraBiotics Pharmaceuticals, Inc.
Delaware
|
0-29993 | 94-3200380 | ||
(State or other jurisdiction
|
(Commission | (IRS Employer | ||
of incorporation)
|
File Number) | Identification No.) | ||
2483 East Bayshore Road, Suite 100
Palo Alto, California 94303
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (650) 526-6800
| Not Applicable | ||
| (Former name or former address, if changed since last report.) |
| Item 5. Other Events. | ||||||||
| Item 7. Financial Statements and Exhibits. | ||||||||
| SIGNATURE | ||||||||
| INDEX TO EXHIBITS | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 5. Other Events.
On June 3, 2004, IntraBiotics Pharmaceuticals, Inc. announced that the underwriters of its public offering have notified IntraBiotics that they will exercise their option to purchase an additional 450,000 shares to cover over-allotments. A copy of the related press release is being filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.
Item 7. Financial Statements and Exhibits.
| (c) | Exhibits. The following documents are filed as exhibits to this report: |
| 99.1 | Press Release, dated June 3, 2004, entitled “IntraBiotics Announces Exercise of Over-Allotment Option.” |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| INTRABIOTICS PHARMACEUTICALS, INC. | ||
Date: June 7, 2004 |
||
| /s/ David Tucker | ||
| David Tucker | ||
| Principal Financial Officer |